BioNTech SE(BNTX)Earnings, Financials & Key Ratios
BNTX•NASDAQ
Price updated Jun 19, 2026
AboutBioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.Show more
- Revenue$2.76B+0.2%
- EBITDA-$256M+74.8%
- Net Income-$1.09B-64.0%
- EPS (Diluted)-4.51-62.8%
- Gross Margin77.64%-3.3%
- EBITDA Margin-9.29%+74.8%
- Operating Margin-22.63%+52.6%
- Net Margin-39.59%-63.7%
- ROE-5.65%-68.4%
BNTX Key Insights
BioNTech SE (BNTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y sales CAGR of 41.7%
- ✓Healthy 5Y average net margin of 13.9%
- ✓Trading at only 1.0x book value
✗Weaknesses
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when BNTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BNTX Price & Volume
BioNTech SE (BNTX) stock price & volume — 10-year historical chart
Loading chart...
BNTX Growth Metrics
BioNTech SE (BNTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years41.71%
3 Years-45.8%
TTM4.01%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-70.34%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-64.79%
Return on Capital
10 Years23.13%
5 Years57.71%
3 Years-2.07%
Last Year-3.13%
BNTX Recent Earnings
BioNTech SE (BNTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (60%)●Beat Revenue 5/12 qtrs (50%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$2.28+9.5%
$2.52
Rev
$136M-34.2%
$207M
Q2 2026
Mar 10, 2026Metric
Actual
Est
EPS
$0.38-72.7%
$0.22
Rev
$1.1B+18.1%
$902M
Q4 2025
Nov 3, 2025Metric
Actual
Est
EPS
$0.14+87.5%
$1.12
Rev
$1.8B+110.9%
$844M
Q3 2025
Aug 4, 2025Metric
Actual
Est
EPS
$1.82+32.3%
$2.69
Rev
$307M+72.7%
$178M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $2.28vs $2.52+9.5% | $136Mvs $207M-34.2% |
| Q2 2026 | Mar 10, 2026 | $0.38vs $0.22-72.7% | $1.1Bvs $902M+18.1% |
| Q4 2025 | Nov 3, 2025 | $0.14vs $1.12+87.5% | $1.8Bvs $844M+110.9% |
| Q3 2025 | Aug 4, 2025 | $1.82vs $2.69+32.3% | $307Mvs $178M+72.7% |
Based on last 12 quarters of dataView full earnings history →
BNTX Peer Comparison
BioNTech SE (BNTX) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 MRNA | 25.37B | 63.96 | -8.81 | -39.23% | -143.55% | -36.73% | 0.22 | |
 PFE | 143.46B | 25.22 | 18.54 | -1.65% | 11.83% | 8.34% | 0.78 | |
 NVAX | 1.5B | 9.13 | 3.59 | 64.69% | -14.73% | |||
 ARCT | 214.03M | 7.53 | -3.14 | -51.43% | -173.47% | -36.55% | 0.12 | |
 REGN | 63.37B | 609.94 | 14.70 | 0.99% | 29.65% | 14.32% | 0.09 | |
 VRTX | 114.88B | 451.63 | 29.48 | 9.57% | 35.4% | 23.93% | 0.21 | |
 BMRN | 10.52B | 54.69 | 30.38 | 12.87% | 8.29% | 4.41% | 0.11 | |
 ALNY | 37.1B | 278.09 | 119.35 | 65.19% | 13.46% | 98.29% | 1.62 |
Compare BNTX vs Peers
BioNTech SE (BNTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BNTX Income Statement
BioNTech SE (BNTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 61.6M | 127.58M | 108.6M | 482.3M | 18.98B | 17.31B | 3.82B | 2.75B | 2.76B |
Revenue Growth % | - | 107.11% | -14.87% | 344.11% | 3834.63% | -8.78% | -77.94% | -27.96% | 0.2% |
Cost of Goods Sold | 9.32M | 13.69M | 17.4M | 59.3M | 2.91B | 3B | 599.8M | 541.3M | 616.47M |
COGS % of Revenue | 15.13% | 10.73% | 16.02% | 12.3% | 15.34% | 17.3% | 15.71% | 19.68% | 22.36% |
Gross Profit | 52.28M▲ 0% | 113.89M▲ 117.8% | 91.2M▼ 19.9% | 423M▲ 363.8% | 16.07B▲ 3697.9% | 14.32B▼ 10.9% | 3.22B▼ 77.5% | 2.21B▼ 31.4% | 2.14B▼ 3.2% |
Gross Margin % | 84.87% | 89.27% | 83.98% | 87.7% | 84.66% | 82.7% | 84.29% | 80.32% | 77.64% |
Gross Profit Growth % | - | 117.84% | -19.92% | 363.82% | 3697.92% | -10.89% | -77.51% | -31.36% | -3.15% |
Operating Expenses | 113.56M | 167.74M | 272.7M | 505.4M | 781.4M | 1.67B | 2.53B | 3.52B | 2.76B |
OpEx % of Revenue | 184.35% | 131.48% | 251.1% | 104.79% | 4.12% | 9.66% | 66.22% | 128.1% | 100.27% |
Selling, General & Admin | 29.49M | 27.07M | 43.3M | 108.5M | 327.2M | 541.2M | 557.7M | 599M | 698.2M |
SG&A % of Revenue | 47.88% | 21.21% | 39.87% | 22.5% | 1.72% | 3.13% | 14.6% | 21.77% | 25.33% |
Research & Development | 85.5M | 143.07M | 226.5M | 645M | 949.2M | 1.54B | 1.78B | 2.25B | 2.02B |
R&D % of Revenue | 138.8% | 112.14% | 208.56% | 133.73% | 5% | 8.88% | 46.69% | 81.94% | 73.34% |
Other Operating Expenses | -1.43M | -2.39M | 2.9M | -248.1M | -495M | -405.3M | 188M | 670.9M | 44M |
Operating Income | -61.28M▲ 0% | -53.85M▲ 12.1% | -181.5M▼ 237.0% | -82.4M▲ 54.6% | 15.28B▲ 18648.3% | 12.64B▼ 17.3% | 690.4M▼ 94.5% | -1.31B▼ 290.4% | -623.87M▲ 52.5% |
Operating Margin % | -99.48% | -42.21% | -167.13% | -17.08% | 80.54% | 73.03% | 18.08% | -47.77% | -22.63% |
Operating Income Growth % | - | 12.11% | -237.02% | 54.6% | 18648.3% | -17.28% | -94.54% | -290.37% | 52.53% |
EBITDA | -50.75M | -31.87M | -147.6M | -43.7M | 15.36B | 12.77B | 873.8M | -1.02B | -256.17M |
EBITDA Margin % | -82.39% | -24.98% | -135.91% | -9.06% | 80.94% | 73.75% | 22.88% | -36.94% | -9.29% |
EBITDA Growth % | - | 37.2% | -363.13% | 70.39% | 35246.45% | -16.88% | -93.16% | -216.31% | 74.79% |
D&A (Non-Cash Add-back) | 10.53M | 21.98M | 33.9M | 38.7M | 75.2M | 123.3M | 183.4M | 298M | 367.69M |
EBIT | -85.23M | -45.94M | -177.7M | -143.8M | 14.93B | 12.97B | 1.19B | -665.1M | -623.87M |
Net Interest Income | 1.4M | 284.04K | 62.1K | -408.5K | -4.07M | 31.55M | 343.55M | -13.16M | 238.6M |
Interest Income | 2.06M | 2.06M | 1.76M | 1.46M | 1.56M | 47.37M | 351.31M | 0 | 252.24M |
Interest Expense | 651.44K | 1.78M | 1.69M | 1.86M | 5.63M | 15.82M | 7.76M | 13.16M | 13.64M |
Other Income/Expense | -24.63M | 6.19M | 2.1M | -63.4M | -237.4M | 311.4M | 495.7M | 636.6M | -385.46M |
Pretax Income | -85.91M▲ 0% | -47.66M▲ 44.5% | -179.4M▼ 276.4% | -145.8M▲ 18.7% | 15.05B▲ 10419.9% | 12.95B▼ 13.9% | 1.19B▼ 90.8% | -677.7M▼ 157.1% | -1.01B▼ 48.9% |
Pretax Margin % | -139.46% | -37.36% | -165.19% | -30.23% | 79.29% | 74.83% | 31.06% | -24.63% | -36.61% |
Income Tax | 45K | 600K | -200K | -161M | 4.75B | 3.52B | 255.8M | -12.4M | 81.93M |
Effective Tax Rate % | -0.05% | -1.26% | 0.11% | 110.43% | 31.59% | 27.17% | 21.57% | 1.83% | -8.12% |
Net Income | -85.65M▲ 0% | -48.02M▲ 43.9% | -179.1M▼ 273.0% | 15.2M▲ 108.5% | 10.29B▲ 67613.8% | 9.43B▼ 8.3% | 930.3M▼ 90.1% | -665.3M▼ 171.5% | -1.09B▼ 64.0% |
Net Margin % | -139.05% | -37.64% | -164.92% | 3.15% | 54.24% | 54.5% | 24.36% | -24.18% | -39.59% |
Net Income Growth % | - | 43.94% | -272.98% | 108.49% | 67613.82% | -8.34% | -90.14% | -171.51% | -64.03% |
Net Income (Continuing) | -85.95M | -48.26M | -179.2M | 15.2M | 10.29B | 9.43B | 930.3M | -665.3M | -1.09B |
Discontinued Operations | 91.29K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 1.09M | 847K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.38▲ 0% | -0.21▲ 44.7% | -0.85▼ 304.8% | 0.06▲ 106.7% | 41.21▲ 72198.2% | 37.09▼ 10.0% | 3.83▼ 89.7% | -2.77▼ 172.3% | -4.51▼ 62.8% |
EPS Growth % | - | 44.74% | -304.76% | 106.71% | 72198.25% | -10% | -89.67% | -172.32% | -62.82% |
EPS (Basic) | -0.38 | -0.21 | -0.85 | 0.06 | 43.87 | 38.08 | 3.87 | -2.77 | -4.51 |
Diluted Shares Outstanding | 226.86M | 226.86M | 211.5M | 248.53M | 259.7M | 249.8M | 242.7M | 240.4M | 241.7M |
Basic Shares Outstanding | 226.86M | 226.86M | 211.5M | 235.44M | 244M | 243.3M | 240.6M | 240.4M | 241.7M |
Dividend Payout Ratio | - | - | - | - | - | 5.13% | - | - | - |
BNTX Balance Sheet
BioNTech SE (BNTX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 189.64M | 448.96M | 560.15M | 1.67B | 15.07B | 21.92B | 19.53B | 18.8B | 16.14B |
Cash & Short-Term Investments | 172.35M | 411.83M | 520.83M | 1.35B | 2.07B | 14.06B | 16.55B | 16.78B | 14.83B |
Cash Only | 172.11M | 411.5M | 519.15M | 1.21B | 1.69B | 13.88B | 11.66B | 9.76B | 7.67B |
Short-Term Investments | 246K | 336K | 1.68M | 137.2M | 381.6M | 189.4M | 4.89B | 7.02B | 7.16B |
Accounts Receivable | 4.58M | 28.44M | 11.91M | 165.5M | 12.38B | 7.15B | 2.34B | 1.52B | 984.48M |
Days Sales Outstanding | 27.11 | 81.37 | 40.04 | 125.25 | 238.16 | 150.68 | 223.62 | 202.18 | 130.35 |
Inventory | 3.88M | 5.79M | 12.07M | 64.1M | 502.5M | 439.6M | 357.7M | 283.3M | 110.65M |
Days Inventory Outstanding | 151.83 | 154.35 | 253.26 | 394.54 | 63 | 53.57 | 217.67 | 191.03 | 65.52 |
Other Current Assets | 8.83M | 12.25M | 15.34M | 89.9M | 113.4M | 271.9M | 280.9M | 212.7M | 210.71M |
Total Non-Current Assets | 185.08M | 204.03M | 237.5M | 651.7M | 758.5M | 1.36B | 3.48B | 3.73B | 5.84B |
Property, Plant & Equipment | 101.52M | 115.97M | 148.06M | 326M | 520.4M | 821.1M | 971.6M | 1.18B | 1.29B |
Fixed Asset Turnover | 0.61x | 1.10x | 0.73x | 1.48x | 36.47x | 21.08x | 3.93x | 2.32x | 2.14x |
Goodwill | 534K | 534K | 2.98M | 53.7M | 57.8M | 61.2M | 362.5M | 380.6M | 367.74M |
Intangible Assets | 83M | 87.51M | 84.05M | 103.8M | 144.6M | 158.5M | 804.1M | 790.4M | 1.61B |
Long-Term Investments | 19K | 18K | 0 | 0 | 21.3M | 80.2M | 1.18B | 1.25B | 2.49B |
Other Non-Current Assets | -2K | -1K | 2.4M | 168.2M | 14.4M | 6.5M | 83.4M | 36.1M | 76.97M |
Total Assets | 374.71M▲ 0% | 652.99M▲ 74.3% | 797.65M▲ 22.2% | 2.32B▲ 190.7% | 15.83B▲ 582.8% | 23.28B▲ 47.0% | 23.01B▼ 1.2% | 22.53B▼ 2.1% | 21.98B▼ 2.4% |
Asset Turnover | 0.16x | 0.20x | 0.14x | 0.21x | 1.20x | 0.74x | 0.17x | 0.12x | 0.13x |
Asset Growth % | - | 74.26% | 22.15% | 190.68% | 582.77% | 47.05% | -1.17% | -2.07% | -2.44% |
Total Current Liabilities | 158.54M | 126.12M | 138.14M | 606M | 3.48B | 2.95B | 2.07B | 2.52B | 2.14B |
Accounts Payable | 52.54M | 41.72M | 20.5M | 102.3M | 160M | 204.1M | 354M | 426.7M | 534.67M |
Days Payables Outstanding | 2.06K | 1.11K | 429.99 | 629.67 | 20.06 | 24.87 | 215.42 | 287.72 | 316.57 |
Short-Term Debt | 0 | 0 | 1.82M | 3M | 129.9M | 36M | 28.1M | 39.5M | 52.18M |
Deferred Revenue (Current) | 77.35M | 66.03M | 0 | 0 | 186.1M | 77.1M | 353.3M | 294.9M | 754.58M |
Other Current Liabilities | 86.73M | 79.16M | 105.63M | 494.6M | 1.44B | 2.04B | 809.6M | 1.76B | 734.39M |
Current Ratio | 1.20x | 3.56x | 4.05x | 2.75x | 4.33x | 7.43x | 9.43x | 7.45x | 7.54x |
Quick Ratio | 1.17x | 3.51x | 3.97x | 2.64x | 4.18x | 7.28x | 9.26x | 7.34x | 7.49x |
Cash Conversion Cycle | -1.88K | -876.64 | -136.69 | -109.88 | 281.1 | 179.38 | 225.87 | 105.49 | -120.7 |
Total Non-Current Liabilities | 264.38M | 259.87M | 166.01M | 340.8M | 455.5M | 272.9M | 689.9M | 595.4M | 621.84M |
Long-Term Debt | 0 | 0 | 14.78M | 152.9M | 171.6M | 176.2M | 191M | 214.7M | 29.89M |
Capital Lease Obligations | 50.35M | 0 | 54.13M | 78.1M | 0 | 0 | 0 | 0 | 185.22M |
Deferred Tax Liabilities | -214.03M | -205.65M | 0 | 0 | 66.7M | 6.2M | 39.7M | 42.4M | 84.26M |
Other Non-Current Liabilities | 214.03M | 0 | 97.11M | 109.8M | 208.2M | 42.1M | 60.7M | 155.3M | 234.5M |
Total Liabilities | 422.92M | 385.99M | 304.15M | 946.8M | 3.94B | 3.22B | 2.76B | 3.12B | 2.76B |
Total Debt | 50.35M | 54.22M | 74.21M | 240.1M | 301.5M | 212.2M | 219.1M | 254.2M | 267.29M |
Net Debt | -121.76M | -357.28M | -444.94M | -970.1M | -1.39B | -13.66B | -11.44B | -9.51B | -7.4B |
Debt / Equity | - | 0.20x | 0.15x | 0.18x | 0.03x | 0.01x | 0.01x | 0.01x | 0.01x |
Debt / EBITDA | - | - | - | - | 0.02x | 0.02x | 0.25x | - | - |
Net Debt / EBITDA | - | - | - | - | -0.09x | -1.07x | -13.10x | - | - |
Interest Coverage | -130.83x | -25.84x | -104.92x | -77.15x | 2651.69x | 819.96x | 153.85x | -50.53x | -45.74x |
Total Equity | -48.21M▲ 0% | 267M▲ 653.9% | 493.49M▲ 84.8% | 1.37B▲ 178.0% | 11.89B▲ 767.0% | 20.06B▲ 68.6% | 20.25B▲ 0.9% | 19.41B▼ 4.1% | 19.22B▼ 1.0% |
Equity Growth % | - | 653.87% | 84.83% | 177.98% | 767.01% | 68.62% | 0.95% | -4.12% | -1% |
Book Value per Share | -0.21 | 1.18 | 2.33 | 5.52 | 45.80 | 80.29 | 83.42 | 80.75 | 79.50 |
Total Shareholders' Equity | -49.3M | 266.15M | 493.49M | 1.37B | 11.89B | 20.06B | 20.25B | 19.41B | 19.22B |
Common Stock | 166.76M | 193.3M | 232.3M | 246.3M | 246.3M | 248.6M | 248.6M | 248.6M | 258.89M |
Retained Earnings | -197.75M | -245.77M | -424.83M | -409.6M | 9.88B | 18.83B | 19.76B | 19.1B | 17.95B |
Treasury Stock | 0 | 0 | -5.53M | -4.8M | -3.8M | -5.3M | -10.8M | -8.6M | -7.7M |
Accumulated OCI | -18.31M | 318.63M | 691.54M | 1.54B | 93.9M | -848.9M | -984.6M | -1.33B | -1.46B |
Minority Interest | 1.09M | 847K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BNTX Cash Flow Statement
BioNTech SE (BNTX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -52.56M | -58.18M | -198.5M | -13.5M | 889.7M | 13.58B | 5.37B | 207.7M | 438M |
Operating CF Margin % | -85.33% | -45.6% | -182.78% | -2.8% | 4.69% | 78.43% | 140.65% | 7.55% | 15.89% |
Operating CF Growth % | - | -10.69% | -241.18% | 93.2% | 6690.37% | 1426.07% | -60.44% | -96.13% | 110.88% |
Net Income | -85.91M | -47.66M | -179.4M | -145.8M | 15.05B | 12.95B | 1.19B | -677.7M | -1.09B |
Depreciation & Amortization | 10.53M | 21.98M | 33.9M | 38.7M | 75.2M | 123.3M | 183.4M | 298M | 367.69M |
Stock-Based Compensation | 5.91M | 7.64M | 30.2M | 32.1M | 93.9M | 108.6M | 51.4M | 100.9M | 0 |
Deferred Taxes | 26.27M | 1.04M | 0 | 0 | 0 | 0 | 0 | 0 | 70.98M |
Other Non-Cash Items | -1.4M | -226K | 300K | 154.6M | -3.6B | -4.13B | -1.62B | -734.1M | 574.01M |
Working Capital Changes | -7.96M | -40.96M | -83.5M | -93.1M | -10.73B | 4.52B | 5.57B | 1.22B | 516.57M |
Change in Receivables | -2.82M | -18.73M | 2.9M | -247.9M | -11.81B | 4.37B | 5.37B | 387.7M | 1.04B |
Change in Inventory | -574K | -1.25M | -5.8M | -49.8M | -438.4M | 62.9M | 81.9M | 74.5M | 170.88M |
Change in Payables | -4.57M | -20.98M | -80.6M | 204.6M | 1.52B | 85.7M | 118.9M | 758.4M | -695.23M |
Cash from Investing | -52.55M | -67.15M | -77.2M | -144.8M | -566.1M | -35.3M | -6.95B | -2.08B | -2.37B |
Capital Expenditures | -57.74M | -67.85M | -38.6M | -66M | -127.5M | -329.2M | -250.1M | -286.5M | -719.44M |
CapEx % of Revenue | 93.74% | 53.19% | 35.54% | 13.68% | 0.67% | 1.9% | 6.55% | 10.41% | 26.1% |
Acquisitions | 4.88M | 727.57K | -6.1M | -60.6M | -20.8M | 0 | -336.9M | 0 | 183.27M |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 5.19M | 706K | -32.5M | -18.2M | -23.1M | -33.5M | -576.59M | -164.6M | 0 |
Cash from Financing | -1.64M | 365.18M | 383.3M | 894.7M | 94.2M | -1.42B | -778.6M | -45.9M | -50.81M |
Debt Issued (Net) | -1.64M | 3.45M | 7.9M | 141.7M | -66.7M | -59.1M | -40.1M | -45.9M | -10.85M |
Equity Issued (Net) | 0 | 361.73M | 375.4M | 753M | 160.9M | -875.9M | -738.5M | 0 | 0 |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | -484.3M | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | -986.4M | -738.5M | 0 | 0 |
Other Financing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -39.96M |
Net Change in Cash | -131.57M▲ 0% | 239.39M▲ 281.9% | 107.6M▼ 55.1% | 691.1M▲ 542.3% | 482.5M▼ 30.2% | 12.18B▲ 2424.8% | -2.21B▼ 118.2% | -1.9B▲ 14.0% | -931.17M▲ 51.0% |
Free Cash Flow | -110.3M▲ 0% | -126.03M▼ 14.3% | -269.6M▼ 113.9% | -98.9M▲ 63.3% | 735.7M▲ 843.9% | 13.21B▲ 1696.1% | 4.67B▼ 64.7% | -244.6M▼ 105.2% | 269.81M▲ 210.3% |
FCF Margin % | -179.07% | -98.79% | -248.25% | -20.51% | 3.88% | 76.34% | 122.18% | -8.89% | 9.79% |
FCF Growth % | - | -14.26% | -113.91% | 63.32% | 843.88% | 1696.13% | -64.69% | -105.24% | 210.31% |
FCF per Share | -0.49 | -0.56 | -1.27 | -0.40 | 2.83 | 52.90 | 19.22 | -1.02 | 1.12 |
FCF Conversion (FCF/Net Income) | 0.61x | 1.21x | 1.11x | -0.89x | 0.09x | 1.44x | 5.77x | -0.31x | -0.40x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BNTX Key Ratios
BioNTech SE (BNTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -43.89% | -47.1% | 1.63% | 155.18% | 59.06% | 4.62% | -3.36% | -5.65% |
Return on Invested Capital (ROIC) | - | - | -280.36% | -27.45% | 210.25% | 112.25% | 6.82% | -10.54% | -4.31% |
Gross Margin | 84.87% | 89.27% | 83.98% | 87.7% | 84.66% | 82.7% | 84.29% | 80.32% | 77.64% |
Net Margin | -139.05% | -37.64% | -164.92% | 3.15% | 54.24% | 54.5% | 24.36% | -24.18% | -39.59% |
Debt / Equity | - | 0.20x | 0.15x | 0.18x | 0.03x | 0.01x | 0.01x | 0.01x | 0.01x |
Interest Coverage | -130.83x | -25.84x | -104.92x | -77.15x | 2651.69x | 819.96x | 153.85x | -50.53x | -45.74x |
FCF Conversion | 0.61x | 1.21x | 1.11x | -0.89x | 0.09x | 1.44x | 5.77x | -0.31x | -0.40x |
Revenue Growth | - | 107.11% | -14.87% | 344.11% | 3834.63% | -8.78% | -77.94% | -27.96% | 0.2% |
Related:BNTX Dividend History·BNTX Revenue History·BNTX Price History·BNTX P/E History·BNTX Financial Ratios·BNTX Institutional Holders
BNTX Frequently Asked Questions
BioNTech SE (BNTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
BioNTech SE (BNTX) reported $2.86B in revenue for fiscal year 2025. This represents a 4545% increase from $61.6M in 2017.
BioNTech SE (BNTX) grew revenue by 0.2% over the past year. Growth has been modest.
BioNTech SE (BNTX) reported a net loss of $1.13B for fiscal year 2025.
Dividend & Returns
BioNTech SE (BNTX) has a return on equity (ROE) of -5.7%. Negative ROE indicates the company is unprofitable.
BioNTech SE (BNTX) generated $276.7M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.